Hamilton, Alina M.
Walens, Andrea
Van Alsten, Sarah C.
Olsson, Linnea T.
Nsonwu-Farley, Joseph
Gao, Xiaohua
Kirk, Erin L.
Perou, Charles M.
Carey, Lisa A.
Troester, Melissa A.
Abdou, Yara
Funding for this research was provided by:
National Cancer Institute of the National Institutes of Health (F31CA257388, T32CA057726, T32CA057726, P50-CA058223, P50-CA058223, R01CA253450, P50-CA058223)
Susan G. Komen (OGUNC1202)
NC Triangle affiliate of Susan G. Komen for the Cure (SAC210102)
U.S. Department of Defense (HT94252310235)
UNC Center for Health Innovation Pilot Award program
METAvivor Health Disparities in MBC Research Award
Article History
Received: 19 October 2023
Accepted: 20 February 2024
First Online: 21 March 2024
Declarations
:
: This study was approved by the University of North Carolina at Chapel Hill (UNC-CH) School of Medicine Institutional Review Board in accordance with the revised U.S. Common Rule.
: All participants provided written informed consent.
: C.M.P is an equity stockholder and consultant of BioClassifier LLC; C.M.P is also listed as an inventor on patent applications for the Breast PAM50 Subtyping assay. The other authors declare no competing interests. The University of North Carolina, Chapel Hill has a license of intellectual property interest in GeneCentric Diagnostics and BioClassifier, LLC, which may be used in this study. The University of North Carolina, Chapel Hill may benefit from this interest that is/are related to this research. The terms of this arrangement have been reviewed and approved by the University of North Carolina, Chapel Hill Conflict of Interest Program in accordance with its conflict of interest policies.